Interferon deal

The agreement reduced the initial cash payment necessary to reacquire the rights from $12 million to $3 million.

IFSC said the event was the final piece in a strategy to regain the rights to the product, an intralesional treatment of refractory or reccuring external genital warts, in order to enter into an agreement with another pharmaceutical company. IFSC regained U.K. and European rights to the product from a Purdue affiliate in January 1994. ...